Muscle-specific increased expression of JAG1 improves the skeletal muscle phenotype in dystrophin-deficient mice
- PMID: 40986346
- PMCID: PMC12501121
- DOI: 10.1073/pnas.2506437122
Muscle-specific increased expression of JAG1 improves the skeletal muscle phenotype in dystrophin-deficient mice
Abstract
Therapeutic strategies for Duchenne muscular dystrophy (DMD) will likely require complementary approaches. One possibility is to explore genetic modifiers that improve muscle regeneration and function. The beneficial effects of the overexpression of Jagged-1 were described in escaper golden retriever muscular dystrophy (GRMD) dogs that had a near-normal life and validated in dystrophin-deficient zebrafish. To clarify the underlying biology of JAG1 overexpression in dystrophic muscles, we generated a transgenic mouse (mdx5cv-JAG1) model that lacks dystrophin and overexpresses human JAG1 in striated muscles. Skeletal muscles from mdx5cv-JAG1 and mdx5cv mice were studied at 1-, 4-, and 12-mo time points. JAG1 expression in mdx5cv-JAG1 increased by 3 to 5 times compared to mdx5cv. Consequently, mdx5cv-JAG1 muscles were significantly bigger and stronger than dystrophic controls, along with an increased number of myofibers. Proteomics data show increased dysferlin in mdx5cv-JAG1 muscles and an association of the histone methyltransferase Nsd1 with the phenotype. Our data support the positive effect of JAG1 overexpression in dystrophic muscles.
Keywords: Duchenne muscular dystrophy; Jagged-1; genetic modifier; mouse model; physiology.
Conflict of interest statement
Competing interests statement:L.M.K. is on the scientific advisory board of Dyne, Myofinity, Somite, and Elenae Therapeutics. He also consults with Advertent Biotherapeutics and PeterBio. M.R.L. became an employee of Vertex Pharmaceuticals at the time of the paper’s submission. T.Y.Z. is an employee of Sanofi.
Update of
-
Muscle-specific increased expression of JAG1 improves skeletal muscle phenotype in dystrophin-deficient mice.bioRxiv [Preprint]. 2025 Mar 14:2025.03.12.642857. doi: 10.1101/2025.03.12.642857. bioRxiv. 2025. Update in: Proc Natl Acad Sci U S A. 2025 Sep 30;122(39):e2506437122. doi: 10.1073/pnas.2506437122. PMID: 40161820 Free PMC article. Updated. Preprint.
References
-
- Koenig M., et al. , Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509–517 (1987). - PubMed
-
- Hoffman E. P., Brown R. H. Jr., Kunkel L. M., Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987). - PubMed
-
- Emery A. E., Population frequencies of inherited neuromuscular diseases–A world survey. Neuromuscul. Disord. 1, 19–29 (1991). - PubMed
MeSH terms
Substances
Grants and funding
- https://doi.org/10.55762/MDA.1291397.pc.gr.198128/Muscular Dystrophy Association (MDA)
- NA/Defeat Duchenne Canada
- 21904/French Muscular Dystrophy Association (AFM)
- 10.55762/pc.gr.157029/Muscular Dystrophy Association (MDA)
- K99AR080197/HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NA/Office of Faculty Development at Boston Children's Hospital
- AHA18POST34070039/American Heart Association (AHA)
- R00CA273170/HHS | NIH | National Cancer Institute (NCI)
- R01AR064300/HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NA/Bernard F. and Alva B. Gimbel Foundation (Bernard F. and Alva B. Gimbel Foundation, Inc.)
- P50HD105351/BCM | Intellectual and Developmental Disabilities Research Center (IDDRC)
- 404161/2019-7/Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- gm067945/GF/NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
